AMO Pharma AMO-02 cDM1 trial design
Analysis based on 6 articles · First reported Jul 06, 2026 · Last updated Jul 06, 2026
The agreement de-risks the clinical development pathway for AMO-02, potentially increasing the asset's value for AMO Pharma and its investors. However, as a privately held company, direct market impact is limited; the news may positively affect sentiment in the rare disease biotech sector.
AMO Pharma, a privately held clinical-stage biopharmaceutical company, announced on July 6, 2026, that it has reached agreement with the U.S. United States — Food and Drug Administration (FDA), the U.K. United Kingdom — Medicines and Healthcare products Regulatory Agency (MHRA), and Canada — Health Canada on the design of a registrational clinical study for its investigational therapy AMO-02 (oral tideglusib) in congenital myotonic dystrophy type 1 (cDM1). The study will use hospitalization as the primary efficacy endpoint, supported by functional assessments as secondary outcomes. The company plans to initiate the study in Q3 2026. cDM1 is a rare, inherited neuromuscular disorder with limited treatment options.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard